Biote Corp

Biote Corp's capital structure is characterized by a negative total equity of $58.54 million and a debt-to-equity ratio of -2.14, indicating a leveraged position with liabilities exceeding assets. The company's liquidity is assessed as medium, with a current ratio of 1.22, suggesting it can cover short-term obligations but with limited buffer. Free cash flow of $28.33 million supports operational flexibility, though the negative net cash position raises concerns about long-term solvency. Profitability metrics show a return on assets (ROA) of 25.13%, which is strong relative to the industry median of 18.5% for Professional Information Services. However, the return on equity (ROE) is negative at -46.2%, reflecting the company's negative equity position and high leverage. Operating income of $35.55 million and a gross margin of 71.45% indicate efficient operations, but the net income of $27.05 million is constrained by interest and debt servicing costs. Geographically, Biote Corp's revenue is concentrated in the pharmaceuticals sector, as per its classification, with no disclosed geographic diversification in the latest financials. This concentration increases exposure to sector-specific risks, including regulatory changes and market volatility. The company's growth trajectory is mixed. Revenue of $192.22 million in the latest period shows a 12.3% year-over-year increase, but the outlook for the current fiscal year (FY) is for a 5.1% decline in revenue, with a further 3.8% contraction expected in the next FY. This suggests a slowdown in demand or pricing pressures in the pharmaceuticals sector. Risk factors include a high debt load, with long-term debt of $125.53 million, and a negative net cash position. The risk assessment indicates a low dilution potential, with no significant changes in shares outstanding between basic and diluted shares. However, the company's negative equity and high leverage increase credit risk and may limit access to additional financing. Recent events include a price target range from $2.00 to $4.00, with a mean of $2.97 and a median of $3.00, reflecting analyst optimism despite the company's financial challenges. The mean recommendation of 2.00 (on a 1-5 scale) suggests a generally positive outlook, with three "buy" ratings and one "hold".